In support of this proposal, drug resistant prostate cancer cell lines have been shown to have enhanced expression of Oct4 and several target genes (MIDI, MYB, IL1RN, RPS27 and CUGBP2)[60]. This evidence concerns the gene POU5F1 and Familial prostate cancer.